 Subjects will be exposed under controlled clinical facilities and medical monitoring to APerth162009 H3N2 or human rhinovirus hRV-16 to gauge Ampligens effectiveness against those, and potentially other viruses Subjects will be exposed under controlled clinical facilities and medical monitoring to APerth162009 H3N2 or human rhinovirus hRV-16 to gauge Ampligens effectiveness against those, and potentially other viruses 